{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T05:15:22Z","timestamp":1783055722405,"version":"3.54.6"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Orthop Trauma Surg"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Tranexamic acid (TXA) effectively reduces blood loss and transfusion requirements in shoulder arthroplasty. However, concerns regarding thromboembolic, neurologic, cardiac, and renal complications have limited its use in medically high-risk patients. This study evaluated temporal trends and the safety of TXA in high-risk patients undergoing total shoulder arthroplasty (TSA).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective cohort study was conducted using TriNetX, identifying patients who underwent shoulder arthroplasty (2012\u20132025). Patients were stratified by preexisting high-risk conditions, including prior thromboembolism, renal failure, atrial fibrillation, seizure disorders, and visual disturbances. Within each subgroup, patients receiving TXA were propensity score\u2013matched to those who did not. Perioperative TXA utilization trends were assessed. Ninety-day postoperative outcomes were compared, including transfusion requirements, thromboembolic events, cardiac complications, renal failure, neurologic events, infections, readmissions, emergency department visits, and mortality. Outcomes were reported as odds ratios (ORs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Reported perioperative TXA use began in 2012 and increased through 2025, with over 70% of patients in both standard- and high-risk cohorts receiving TXA. TXA use was associated with significantly lower transfusion rates (OR range 0.53\u20130.62) and readmissions (OR range 0.63\u20130.75) across all high-risk cohorts (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009\u2264\u20090.01). TXA use was not associated with increased risk of deep vein thrombosis, pulmonary embolism, stroke, or postoperative seizures in any subgroup. Notably, TXA demonstrated a protective association against myocardial infarction, cardiac ischemia, acute renal failure, and mortality in select high-risk populations. No increase in infection-related complications was observed.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients undergoing shoulder arthroplasty, TXA use was safe across multiple high-risk medical populations and was consistently associated with lower transfusion and readmission rates, with reduced mortality in select cohorts. These findings support the broader use of TXA for blood conservation in shoulder arthroplasty, even among patients with traditionally high-risk comorbidities, while underscoring the need for future prospective, shoulder-specific safety studies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Level of evidence<\/jats:title>\n                    <jats:p>III, Retrospective Cohort Study<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00402-026-06406-0","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:17:00Z","timestamp":1783052220000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Tranexamic acid in high-risk shoulder arthroplasty patients: safety across thromboembolic, cardiac, renal, and neurologic risk profiles"],"prefix":"10.1007","volume":"146","author":[{"given":"Tarishi","family":"Parmar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akin","family":"Adio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asim","family":"Handy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Daher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Kellish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Abboud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"issue":"10","key":"6406_CR1","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/j.jse.2016.02.002","volume":"25","author":"JT Abildgaard","year":"2016","unstructured":"Abildgaard JT, McLemore R, Hattrup SJ (2016) Tranexamic acid decreases blood loss in total shoulder arthroplasty and reverse total shoulder arthroplasty. J Shoulder Elb Surg 25(10):1643\u20131648. https:\/\/doi.org\/10.1016\/j.jse.2016.02.002","journal-title":"J Shoulder Elb Surg"},{"issue":"1","key":"6406_CR2","doi-asserted-by":"publisher","first-page":"100614","DOI":"10.1016\/j.xrrt.2025.100614","volume":"6","author":"BJ Ambrose Martino","year":"2026","unstructured":"Ambrose Martino BJ, Northrop M, Rogalski BL, Eichinger JK, Friedman RJ (2026) Tranexamic acid in shoulder surgery: a comprehensive review of efficacy, safety, and clinical use. JSES Rev Rep Tech 6(1):100614. https:\/\/doi.org\/10.1016\/j.xrrt.2025.100614","journal-title":"JSES Rev Rep Tech"},{"key":"6406_CR3","doi-asserted-by":"publisher","unstructured":"Barcel DA, Friedman RJ (2016) Minimizing blood transfusions in total shoulder arthroplasty. Ann Jt. https:\/\/doi.org\/10.21037\/aoj.2016.06.04","DOI":"10.21037\/aoj.2016.06.04"},{"issue":"2","key":"6406_CR4","doi-asserted-by":"publisher","first-page":"e70020","DOI":"10.1002\/anr3.70020","volume":"13","author":"B Chevalley","year":"2025","unstructured":"Chevalley B, Betello M, Blavakis E, Malcl\u00e8s A, Maillard J (2025) Postoperative bilateral visual loss after a single dose of tranexamic acid. Anaesth Rep 13(2):e70020. https:\/\/doi.org\/10.1002\/anr3.70020","journal-title":"Anaesth Rep"},{"issue":"1","key":"6406_CR5","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jses.2018.01.002","volume":"2","author":"GL Cvetanovich","year":"2018","unstructured":"Cvetanovich GL, Fillingham YA, O\u2019Brien M, Forsythe B, Cole BJ, Verma NN et al (2018) Tranexamic acid reduces blood loss after primary shoulder arthroplasty: a double-blind, placebo-controlled, prospective, randomized controlled trial. JSES Open Access 2(1):23\u201327. https:\/\/doi.org\/10.1016\/j.jses.2018.01.002","journal-title":"JSES Open Access"},{"issue":"6","key":"6406_CR6","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1530\/EOR-23-0140","volume":"9","author":"X Dang","year":"2024","unstructured":"Dang X, Liu M, Yang Q, Jiang J, Liu Y, Sun H et al (2024) Tranexamic acid may benefit patients with preexisting thromboembolic risk undergoing total joint arthroplasty: a systematic review and meta-analysis. EFORT Open Rev 9(6):467\u2013478. https:\/\/doi.org\/10.1530\/EOR-23-0140","journal-title":"EFORT Open Rev"},{"issue":"2S1","key":"6406_CR7","doi-asserted-by":"publisher","first-page":"S21","DOI":"10.1016\/j.arth.2024.10.050","volume":"40","author":"M Enayatollahi","year":"2025","unstructured":"Enayatollahi M, Azboy I, Dietz MJ, Aunon A, Heshmat R, Dragosloveanu S et al (2025) What are the contraindications, if any, for the use of tranexamic acid during knee or hip arthroplasty? J Arthroplasty 40(2S1):S21\u2013S24. https:\/\/doi.org\/10.1016\/j.arth.2024.10.050","journal-title":"J Arthroplasty"},{"issue":"7","key":"6406_CR8","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1016\/j.jse.2016.11.039","volume":"26","author":"AJ Grier","year":"2017","unstructured":"Grier AJ, Bala A, Penrose CT, Seyler TM, Bolognesi MP, Garrigues GE (2017) Analysis of complication rates following perioperative transfusion in shoulder arthroplasty. J Shoulder Elb Surg 26(7):1203\u20131209. https:\/\/doi.org\/10.1016\/j.jse.2016.11.039","journal-title":"J Shoulder Elb Surg"},{"issue":"2","key":"6406_CR9","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.jse.2008.08.005","volume":"18","author":"KI Gruson","year":"2009","unstructured":"Gruson KI, Accousti KJ, Parsons BO, Pillai G, Flatow EL (2009) Transfusion after shoulder arthroplasty: an analysis of rates and risk factors. J Shoulder Elb Surg 18(2):225\u2013230. https:\/\/doi.org\/10.1016\/j.jse.2008.08.005","journal-title":"J Shoulder Elb Surg"},{"key":"6406_CR10","doi-asserted-by":"publisher","first-page":"e3054","DOI":"10.1136\/bmj.e3054","volume":"344","author":"K Ker","year":"2012","unstructured":"Ker K, Edwards P, Perel P, Shakur H, Roberts I (2012) Effect of tranexamic acid on surgical bleeding: systematic review and cumulative meta-analysis. BMJ 344:e3054. https:\/\/doi.org\/10.1136\/bmj.e3054","journal-title":"BMJ"},{"issue":"7","key":"6406_CR11","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1136\/rapm-2020-101301","volume":"45","author":"MA Kirksey","year":"2020","unstructured":"Kirksey MA, Wilson LA, Fiasconaro M, Poeran J, Liu J, Memtsoudis SG (2020) Tranexamic acid administration during total joint arthroplasty surgery is not associated with an increased risk of perioperative seizures: a national database analysis. Reg Anesth Pain Med 45(7):505\u2013508. https:\/\/doi.org\/10.1136\/rapm-2020-101301","journal-title":"Reg Anesth Pain Med"},{"issue":"3","key":"6406_CR12","doi-asserted-by":"publisher","first-page":"e12456","DOI":"10.1002\/emp2.12456","volume":"2","author":"AS Kiser","year":"2021","unstructured":"Kiser AS, Cooper GL, Napier JD, Howington GT (2021) Color vision disturbances secondary to oral tranexamic acid. J Am Coll Emerg Phys Open 2(3):e12456. https:\/\/doi.org\/10.1002\/emp2.12456","journal-title":"J Am Coll Emerg Physicians Open"},{"issue":"4","key":"6406_CR13","doi-asserted-by":"publisher","first-page":"585","DOI":"10.2450\/2013.0029-13","volume":"11","author":"SR Leal-Noval","year":"2013","unstructured":"Leal-Noval SR, Mu\u00f1oz M, Asuero M, Contreras E, Garc\u00eda-Erce JA, Llau JV et al (2013) Spanish consensus statement on alternatives to allogeneic blood transfusion: the 2013 update of the Seville document. Blood Transfus 11(4):585\u2013610. https:\/\/doi.org\/10.2450\/2013.0029-13","journal-title":"Blood Transfus"},{"issue":"1","key":"6406_CR14","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/ana.24558","volume":"79","author":"I Lecker","year":"2015","unstructured":"Lecker I, Wang D-S, Whissell PD, Avramescu S, Mazer CD, Orser BA (2015) Tranexamic acid\u2013associated seizures: causes and treatment. Ann Neurol 79(1):18. https:\/\/doi.org\/10.1002\/ana.24558","journal-title":"Ann Neurol"},{"key":"6406_CR15","doi-asserted-by":"publisher","first-page":"111417","DOI":"10.1016\/j.jclinane.2024.111417","volume":"94","author":"C-W Liu","year":"2024","unstructured":"Liu C-W, Anih J, Lebedeva V, Gungor A, Wang C, Park L et al (2024) Kidney disease in trials of perioperative tranexamic acid. J Clin Anesth 94:111417. https:\/\/doi.org\/10.1016\/j.jclinane.2024.111417","journal-title":"J Clin Anesth"},{"issue":"3","key":"6406_CR16","doi-asserted-by":"publisher","first-page":"179","DOI":"10.5792\/ksrr.2016.28.3.179","volume":"28","author":"D Liu","year":"2016","unstructured":"Liu D, Dan M, Martinez Martos S, Beller E (2016) Blood management strategies in total knee arthroplasty. Knee Surg Relat Res 28(3):179\u2013187. https:\/\/doi.org\/10.5792\/ksrr.2016.28.3.179","journal-title":"Knee Surg Relat Res"},{"issue":"4","key":"6406_CR17","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1111\/nep.12762","volume":"22","author":"TK-W Ma","year":"2017","unstructured":"Ma TK-W, Chow KM, Kwan BC-H, Leung CB, Szeto CC, Li PK-T (2017) Manifestation of tranexamic acid toxicity in chronic kidney disease and kidney transplant patients: a report of four cases and review of literature. Nephrol Carlton Vic 22(4):316\u2013321. https:\/\/doi.org\/10.1111\/nep.12762","journal-title":"Nephrol Carlton Vic"},{"issue":"5","key":"6406_CR18","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.1016\/j.jse.2024.08.051","volume":"34","author":"CK Mayfield","year":"2025","unstructured":"Mayfield CK, Liu KC, Richardson MK, Freshman RD, Kotlier JL, Fathi A et al (2025) Tranexamic acid use in total shoulder arthroplasty continues to increase and is safe in high-risk patients. J Shoulder Elb Surg 34(5):1138\u20131151. https:\/\/doi.org\/10.1016\/j.jse.2024.08.051","journal-title":"J Shoulder Elb Surg"},{"key":"6406_CR28","doi-asserted-by":"publisher","unstructured":"Nassar M, Abosheaishaa H, Elfert K, Beran A, Ismail A, Mohamed M, Misra A, Essibayi MA, Altschul DJ, Azzam AY et al (2025) TriNetX and real-worldevidence: a critical review of its strengths, limitations, and bias considerations in clinical research. ASIDE Intern Med 1(2):24\u201332. https:\/\/doi.org\/10.71079\/aside.im.03222516","DOI":"10.71079\/aside.im.03222516"},{"issue":"20","key":"6406_CR19","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.2106\/JBJS.21.00172","volume":"103","author":"SB Porter","year":"2021","unstructured":"Porter SB, Spaulding AC, Duncan CM, Wilke BK, Pagnano MW, Abdel MP (2021) Tranexamic acid was not associated with increased complications in high-risk patients with hip fracture undergoing arthroplasty. J Bone Joint Surg Am 103(20):1880\u20131889. https:\/\/doi.org\/10.2106\/JBJS.21.00172","journal-title":"J Bone Joint Surg Am"},{"key":"6406_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/ksa.70124","author":"JR Porto","year":"2025","unstructured":"Porto JR, Lavu MS, Hecht CJ, Asimakis OG, Kaelber DC, Kamath AF (2025) Tranexamic acid lowers transfusions and readmissions in high-risk total knee arthroplasty patients, but neurologic risks remain in patients with seizures or visual disturbances. Knee Surg Sports Traumatol Arthrosc. https:\/\/doi.org\/10.1002\/ksa.70124","journal-title":"Knee Surg Sports Traumatol Arthrosc Off J ESSKA"},{"key":"6406_CR21","doi-asserted-by":"publisher","unstructured":"Rainey JP, Fillingham YA, Hannon CP (2025) Tranexamic acid is safe and effective in reducing blood loss and transfusion rates in nearly all patients undergoing total hip and knee arthroplasty. Arthroplasty Today. https:\/\/doi.org\/10.1016\/j.artd.2025.101868","DOI":"10.1016\/j.artd.2025.101868"},{"issue":"21","key":"6406_CR22","doi-asserted-by":"publisher","first-page":"e10720","DOI":"10.1097\/MD.0000000000010720","volume":"97","author":"N Stoicea","year":"2018","unstructured":"Stoicea N, Moran K, Mahmoud A-R, Glassman A, Ellis T, Ryan J et al (2018) Tranexamic acid use during total hip arthroplasty. Med (Baltim) 97(21):e10720. https:\/\/doi.org\/10.1097\/MD.0000000000010720","journal-title":"Med (Baltim)"},{"issue":"22","key":"6406_CR23","doi-asserted-by":"publisher","first-page":"e7015","DOI":"10.1097\/MD.0000000000007015","volume":"96","author":"C-X Sun","year":"2017","unstructured":"Sun C-X, Zhang L, Mi L-D, Du G-Y, Sun X-G, He S-W (2017) Efficiency and safety of tranexamic acid in reducing blood loss in total shoulder arthroplasty: a systematic review and meta-analysis. Med (Baltim) 96(22):e7015. https:\/\/doi.org\/10.1097\/MD.0000000000007015","journal-title":"Med (Baltim)"},{"issue":"6","key":"6406_CR24","doi-asserted-by":"publisher","first-page":"e210884","DOI":"10.1001\/jamasurg.2021.0884","volume":"156","author":"I Taeuber","year":"2021","unstructured":"Taeuber I, Weibel S, Herrmann E, Neef V, Schlesinger T, Kranke P et al (2021) Association of intravenous tranexamic acid with thromboembolic events and mortality: a systematic review, meta-analysis, and meta-regression. JAMA Surg 156(6):e210884. https:\/\/doi.org\/10.1001\/jamasurg.2021.0884","journal-title":"JAMA Surg"},{"issue":"19","key":"6406_CR25","doi-asserted-by":"publisher","first-page":"2354","DOI":"10.1097\/CM9.0000000000002114","volume":"135","author":"S Tang","year":"2022","unstructured":"Tang S, Zhou Z, Yang J, Kang P, Shen B, Pei F et al (2022) Effects of tranexamic acid on vascular occlusive events and perioperative resuscitation in patients with atrial fibrillation undergoing total joint arthroplasty. Chin Med J (Engl) 135(19):2354. https:\/\/doi.org\/10.1097\/CM9.0000000000002114","journal-title":"Chin Med J (Engl)"},{"issue":"9","key":"6406_CR26","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/anae.16058","volume":"78","author":"SEH Tsan","year":"2023","unstructured":"Tsan SEH, Viknaswaran NL, Cheong CC, Cheah S, Ng KT, Mong SXY et al (2023) Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: a systematic review, meta-analysis and trial sequential analysis. Anaesthesia 78(9):1153\u20131161. https:\/\/doi.org\/10.1111\/anae.16058","journal-title":"Anaesthesia"}],"container-title":["Archives of Orthopaedic and Trauma Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00402-026-06406-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00402-026-06406-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00402-026-06406-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T04:17:02Z","timestamp":1783052222000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00402-026-06406-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6406"],"URL":"https:\/\/doi.org\/10.1007\/s00402-026-06406-0","relation":{},"ISSN":["1434-3916"],"issn-type":[{"value":"1434-3916","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"27 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"244"}}